Oxford Nanopore (LSE: ONT) shares jump as loss narrows and new CEO targets $1 bn revenue scale

Oxford Nanopore Technologies plc (LSE: ONT) shares jumped more than 7% on August 19 after the DNA and RNA sequencing company reported higher first-half revenue, a substantially narrower loss and a new strategic roadmap under Chief Executive Officer Francis Van Parys. Revenue for the six months ended June 30 reached £116.7 million, representing 12.3% constant-currency growth, while the half-year loss narrowed to about £48 million from £71.8 million a year earlier. Clinical and BioPharma were the fastest-growing customer markets, providing evidence that Oxford Nanopore’s attempt to diversify beyond traditional research customers is gaining traction. The tension is that the company still needs a significantly stronger second half to meet FY2026 expectations, with China, the Middle East and the timing of Americas orders remaining constraints and some expected second-half growth coming from collaboration and licensing revenue rather than purely recurring product demand.

Oxford Nanopore shares rose 7.2% to around 130.3 pence in morning London trading, putting the company at the top of the FTSE 250. The reaction reverses part of the damage from July 13, when the shares fell sharply after management warned that first-half revenue had missed its expectations. The August results therefore matter less because revenue itself surprised dramatically, much of the sales picture had already been disclosed, and more because the completed accounts and Van Parys strategy update gave investors better evidence around cost control, market prioritisation and the path toward profitability.

Why did Oxford Nanopore shares rise when first-half revenue had already disappointed investors in July?

The July trading update had already established the difficult part of the story. Oxford Nanopore expected approximately £116.5 million of first-half revenue, around 12% constant-currency growth, after China revenue declined about 16% and Middle East revenue fell approximately 14%. Revenue outside China and the Middle East increased about 16% at constant currencies, but management acknowledged that first-half performance was below its own expectations.

The completed results changed the emphasis.

Actual revenue came in at £116.7 million and the half-year loss fell to roughly £48 million from £71.8 million. That narrowing is important because Oxford Nanopore remains a loss-making growth company whose valuation ultimately depends on demonstrating that revenue expansion can produce operating leverage rather than simply requiring continued increases in spending.

Oxford Nanopore had already reduced its adjusted EBITDA loss from £117.9 million in 2024 to £86.7 million in 2025. The first-half loss reduction therefore extends a broader pattern of financial improvement rather than representing a one-quarter cost exercise. Management continues to target adjusted EBITDA breakeven during FY2027 and cash-flow breakeven thereafter.

For investors, that is arguably the most important part of the August 19 update. Revenue growth can remain volatile because of large research projects, geographical restrictions and contract timing. A consistent reduction in the amount of cash and earnings capacity consumed while the company scales would make the longer-term commercial story materially easier to underwrite.

Are Clinical and BioPharma becoming large enough to change Oxford Nanopore’s growth profile?

Oxford Nanopore’s fastest-growing markets are increasingly outside its traditional academic and research customer base.

Clinical revenue increased 35.4% during the first half, BioPharma rose 25%, Industrial revenue increased 6.2% and Research grew 5.4%. PromethION product-range revenue increased 15.7%, continuing the shift toward Oxford Nanopore’s higher-throughput sequencing systems.

That mix is strategically significant.

In 2025, Research still accounted for about 67% of Oxford Nanopore revenue, compared with approximately 13% from Clinical, 8% from BioPharma and 12% from Applied Industrial customers. Clinical revenue nevertheless grew almost 60% that year, while BioPharma increased more than 30%. The latest first-half figures suggest that those applied markets are continuing to grow considerably faster than Research.

The opportunity is not simply additional revenue. Clinical and BioPharma applications can potentially produce different utilisation patterns from research projects, including repeat testing, regulated workflows, quality-control applications and partnerships embedded within broader diagnostic or pharmaceutical processes.

Oxford Nanopore disclosed developments including a licensing agreement with a global diagnostics company and an agreement with California-based MyOme to incorporate Oxford Nanopore sequencing into a rare-disease platform. Those relationships fit the company’s wider strategy of moving its sequencing technology closer to repeatable clinical and commercial workflows rather than relying primarily on individual research projects.

The next question is scale. High percentage growth from smaller businesses can improve the revenue mix without immediately transforming group economics. The investment case becomes considerably stronger if Clinical and BioPharma continue growing faster than Research for several years and begin contributing a much larger proportion of total sales.

What does Francis Van Parys’ $1 billion revenue ambition actually require from Oxford Nanopore?

Van Parys used his first major strategy update since becoming Chief Executive Officer in March to set a much larger long-term objective: building Oxford Nanopore into a business generating more than $1 billion of annual revenue. He said management had refined where the company’s differentiated technology could create the greatest value and was concentrating people, investment and innovation around selected high-potential applications across BioPharma, Clinical and Research markets.

The scale of the ambition is easy to quantify.

Oxford Nanopore generated £223.9 million of revenue during 2025. Even allowing for currency differences, reaching annual revenue exceeding $1 billion would require the company to become several times larger than it is today. That cannot be achieved simply through incremental penetration of academic sequencing.

It requires Oxford Nanopore to establish meaningful positions in markets where sequencing becomes part of routine workflows.

That explains why Van Parys’ background matters. Before joining Oxford Nanopore, he led Radiometer within Danaher Corporation and previously held senior positions across diagnostics and life sciences businesses. Oxford Nanopore specifically recruited him as the company moves from proving the technological capabilities of nanopore sequencing toward proving that those capabilities can be commercialised at much greater scale.

The $1 billion ambition is therefore best understood as a strategic destination rather than current financial guidance. Oxford Nanopore has not provided a confirmed date for reaching that revenue level.

Why does FY2026 guidance still contain an important question about revenue quality?

Oxford Nanopore has maintained expected FY2026 constant-currency revenue growth of approximately 21% to 25%. However, that range includes additional collaboration and licensing revenue opportunities expected during the second half, some of which management has previously indicated may be non-recurring. Excluding those additional opportunities, underlying constant-currency revenue growth is expected to be closer to 16% to 20%.

That distinction deserves more attention than the headline guidance range.

A licensing payment or collaboration milestone is economically valuable, but it does not necessarily carry the same valuation quality as recurring sequencing consumables or consistently increasing utilisation by clinical and pharmaceutical customers. Investors therefore need to look beyond whether Oxford Nanopore technically reaches 21% to 25% growth and examine what produces that result.

A second-half acceleration driven by rising flow-cell consumption, new Clinical customers and BioPharma workflows would offer stronger evidence of scalable demand. A result heavily dependent on one-off licensing transactions would still improve reported revenue but provide less information about the sustainable growth rate entering 2027.

Management nevertheless expects a materially stronger second half, supported by Applied Markets and secured business ramping up. Gross-margin guidance remains approximately 62%, an important improvement from the 58.6% reported for FY2025.

If Oxford Nanopore can combine stronger second-half revenue with that margin expansion, the mathematics of its FY2027 EBITDA breakeven target would become considerably more convincing.

How serious are Oxford Nanopore’s China and Middle East problems for the wider growth strategy?

China remains one of the clearest external constraints.

First-half revenue there fell approximately 16%, reflecting tighter export-control restrictions and changes to Oxford Nanopore’s commercial operations. Middle East revenue declined around 14% amid geopolitical disruption. The Americas also performed below management expectations because of the timing of customer orders and contract wins.

However, Oxford Nanopore reported approximately 16% constant-currency revenue growth outside China and the Middle East. That reduces the risk of interpreting the first-half slowdown as evidence of a broad collapse in demand for the company’s platform.

The more important strategic issue is whether Oxford Nanopore can become sufficiently diversified that weakness in any one geography does not determine group performance.

Its expansion into Clinical and BioPharma potentially helps because those markets create multiple commercial routes across North America, Europe and other regulated healthcare markets. But diversification does not eliminate geopolitical exposure. Sequencing is an increasingly strategic technology, and export controls, healthcare regulation and government research budgets will remain relevant to growth.

The company therefore needs both geographic diversification and end-market diversification.

Does Oxford Nanopore still have enough cash to reach its FY2027 EBITDA breakeven target?

Cash remains a central part of the investment case because Oxford Nanopore has yet to generate sustainable positive cash flow.

Cash, cash equivalents and other liquid investments stood at approximately £234.5 million at June 30, down from £302.8 million at the end of 2025. The reduction shows that the business continues consuming financial resources even as profitability improves.

The balance sheet remains substantial relative to the current operating loss, but the direction matters. Oxford Nanopore must continue narrowing losses quickly enough that reaching EBITDA breakeven does not require a major deterioration in its financial flexibility.

Management argues that restructuring, gross-margin improvement, pricing changes and cost discipline provide the operating leverage required to reach adjusted EBITDA breakeven in FY2027. Its revised commercial strategy also concentrates spending on markets and applications that management believes offer the highest returns.

That creates a measurable test for the next 18 months. Revenue needs to accelerate without operating expenditure returning to the growth rates typical of an earlier development-stage business.

What would prove Oxford Nanopore’s August share-price rebound is more than relief after the July selloff?

The August 19 rally signals that investors welcomed the smaller loss and clearer strategic focus, but Oxford Nanopore has not yet solved the underlying execution challenge.

The company still has to deliver a much stronger second half, manage continued weakness in China, convert Applied Market momentum into recurring revenue and demonstrate that gross-margin improvement can continue while it scales. At the same time, Van Parys must move the organisation from a technology-led growth model toward one capable of generating repeatable commercial returns.

The most important evidence will therefore come from revenue composition rather than the share price itself.

If Clinical and BioPharma continue expanding above 20% to 30%, PromethION utilisation keeps increasing, gross margin moves toward 62% and cash consumption declines substantially, the FY2027 breakeven target will look increasingly achievable. If FY2026 growth relies disproportionately on non-recurring collaborations while core product growth remains subdued, investors may again question how quickly Oxford Nanopore can translate technological differentiation into durable profitability.

The August results have improved the profitability side of the equation. The next task is proving that the growth required to build a $1 billion-plus revenue company is recurring, scalable and increasingly cash generative.

Key takeaways from Oxford Nanopore’s H1 2026 results and $1 billion revenue ambition

• Oxford Nanopore Technologies reported H1 2026 revenue of £116.7 million, representing 12.3% constant-currency growth.
• The half-year loss narrowed to about £48 million from £71.8 million a year earlier.
• Oxford Nanopore shares rose more than 7% to around 130.3 pence following the results and strategy update.
• Clinical revenue increased 35.4%, while BioPharma revenue grew 25%, considerably faster than Research.
• PromethION revenue increased 15.7%, reinforcing the shift toward higher-throughput sequencing applications.
• Chief Executive Officer Francis Van Parys outlined a longer-term ambition to build Oxford Nanopore into a business generating more than $1 billion in annual revenue.
• China revenue fell approximately 16% and Middle East revenue declined around 14%, remaining major near-term headwinds.
• FY2026 constant-currency revenue growth guidance remains approximately 21% to 25%, including collaboration and licensing opportunities that may include non-recurring revenue.
• Cash and liquid investments declined to approximately £234.5 million from £302.8 million at the end of 2025.
• Oxford Nanopore continues to target adjusted EBITDA breakeven during FY2027, making second-half revenue quality, gross margins and cash consumption the next major tests.